CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban

INTRODUCTION: The aim of this study is to assess the influence of gene CYP2C19, CYP3A4, CYP3A5 and ABCB1 polymorphisms on clopidogrel antiplatelet activity, rivaroxaban concentration equilibrium, and clinical outcomes among patients with acute coronary syndrome and non-valvular atrial fibrillation....

Descripción completa

Detalles Bibliográficos
Autores principales: Sychev, DA, Baturina, OA, Mirzaev, KB, Rytkin, E, Ivashchenko, DV, Andreev, DA, Ryzhikova, KA, Grishina, EA, Bochkov, PO, Shevchenko, RV
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986167/
https://www.ncbi.nlm.nih.gov/pubmed/32158254
http://dx.doi.org/10.2147/PGPM.S234910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986167/
https://www.ncbi.nlm.nih.gov/pubmed/32158254
http://dx.doi.org/10.2147/PGPM.S234910

Ejemplares similares